Better immunotherapies | Agenus
WebAgenus discovers, manufactures, and develops immuno-oncology (I-O) therapeutics. Our vision is to expand the patient population benefiting from I-O through combination approaches that leverage a broad repertoire of antibody therapeutics, adoptive cell therapies (through subsidiary MiNK Therapeutics ), adjuvants and vaccines (through subsidiary ...
Pipeline | Agenus
WebPipeline. We are a clinical-stage immunotherapy company targeting complementary mechanisms to fight cancer, including checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Agenus Inc. - Investor Relations
WebMay 1, 2024 · Agenus is an immuno-oncology company focused on the discovery and development of potentially revolutionary new treatments that leverage the body’s immune system to fight cancer and infectious diseases. Corporate. presentation. Events. SEC. filings. Latest Press Releases. May 1, 2024.
Our History | Agenus
WebAgenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to deliver curative patient outcomes
Team | Agenus
WebOur Team. Leadership. Board of Directors. Advisory Board. Garo H. Armen, PhD. Chairman and Chief Executive Officer. Jennifer Buell, PhD. President and CEO of MiNK Therapeutics. Tracy Mazza Clemente. Chief People Officer. Alfred Dadson. Chief Manufacturing Officer. Nils Eckardt, MD. Chief Medical Affairs Officer. Eric Humes. Chief Quality Officer.
Agenus - Wikipedia
WebAgenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants desugned for use with various vaccines.
Agenus | LinkedIn
WebWebsite. https://agenusbio.com/. Industry. Biotechnology Research. Company size. 201-500 employees. Headquarters. Lexington, Massachusetts. Type. Public Company. Founded. 1994. Specialties....
Agenus Inc. - ESMO 2023: Agenus’ Botensilimab/Balstilimab …
WebOct 21, 2023 · Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell …
Agenus Inc. - Botensilimab/Balstilimab Breakthrough Data …
WebJan 22, 2024 · Botensilimab/Balstilimab (BOT/BAL) shows major tumor regression in 67.5% of Patients with Localized MSS Colorectal Cancer (CRC), a tumor typically unresponsive to IO therapy. The study achieved durable elimination of ctDNA, a critical biomarker for cancer clearance and long-term disease-free survival.
Agenus Inc. - Agenus Completes Enrollment in Randomized …
WebOct 10, 2023 · Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers today announced completion of the planned patient enrollment in ACTIVATE-Colorectal, a randomized Phase 2 trial in advanced colorectal cancer (CRC) evaluating the efficacy and safety of botensilimab (BOT) as monotherapy …
Skip to content